The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
The pharmaceutical landscape is shifting. Direct-to-consumer pricing for medications like GLP-1s is gaining traction. This could reshape how we access and afford treatments for weight loss and metabolic health. Learn how this might affect your wellness.
Emerging research suggests that GLP-1 drugs, originally developed for diabetes and weight loss, may also be effective in treating alcohol and drug addiction. This blog explores the science and potential of these groundbreaking treatments.
This post dives into the complexities of GLP-1 medications, body image, and navigating criticism in your health journey, offering actionable tips for wellness.
A recent recall of Ozempic in Canada highlights the importance of staying informed about your medications. This post explains the recall, its potential implications, and how to stay safe while navigating your health journey.
Jonathan Van Ness recently shared his experience with GLP-1 medications for weight loss. This post delves into the science behind these medications, their impact on metabolic health, and how to make informed choices about your well-being.
Eli Lilly's impressive financial results highlight the growing impact of GLP-1 drugs like Mounjaro and Zepbound in the weight loss arena. This article explores the science behind these medications, their effectiveness, and the competitive landscape.
Curious about GLP-1 medications like Ozempic and their role in weight loss? This blog post dives into the science, potential benefits, and importance of understanding your metabolic health journey for long-term well-being.
Dr. Reddy's faced a setback in Canada for its Semaglutide Injection submission. This news highlights the complexities of bringing vital medications like GLP-1 receptor agonists to market. Here’s what you need to know about this development and its impact on weight loss and health.
New research shows that GLP-1 receptor agonists may significantly reduce asthma exacerbations and the need for steroids in obese patients with asthma. This opens up promising new avenues in metabolic health and asthma management.
